Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

New England Journal of Medicine

23 October Oct 2020 one month ago
  • Salvioni A, Genovese S

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.

Reference

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators. Salvioni A, Genovese S among collaborators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190.

Go to PubMed